3 years ago

Hypothesis: Can neuroendocrine immune (NEI) testing of individual RA patients guide benefits to harms ratio in glucocorticoid therapy?

Maurizio Cutolo, Richard Imrich, Alfonse T Masi
We compliment and endorse the “Official View” by Palmowsky Y and the multidisciplinary experts on their review of guidelines for glucocorticoid (GC) therapy in rheumatoid arthritis (RA) (1). The guidelines generally agreed that GCs are an appropriate option for RA therapy, especially at low doses and for a short duration (1). However, the recommendations lacked evidence and guidance on doses, timing, and duration of GC use. Authors concluded that high-quality studies of GCs in RA are urgently needed (1). This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/acr.23453

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.